Discover and read the best of Twitter Threads about #rxepi

Most recents (4)

We are unveiling new findings about MME/day calcs for #opioids @US_FDA Workshop today. Live blogged in thread below.

Lab notebook, code, equations:
opioiddata.org/studies/equati…
With @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey
#epitwitter #RxEpi #medtwitter
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey Apologies in advance... this is experimental live blogging... sometimes twitter scrambles images on long threads
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey 14 states impose limits on opioid dosage that can be prescribed, ranging from 30 MME to a 120 MME daily maximum. Also third-party payers (insurance, @CMSgov). Analysis by @coreysdavis @amyamnesia of @networkforphl
onlinelibrary.wiley.com/doi/10.1111/ad…
Read 32 tweets
I'm seeing epidemiologists make a logical fallacy about the COVID vax + blood clots. Saying the risk (or rate) is "1 in a million" = misleading
Here’s a quick breakdown on how to do better by #pharmacovigilance (PV) stats
Audience: #epitwitter #datascience #RxEpi Image
2/ Comparing to birth control risks isn't proper. The *type* of clot is different. But also, quantified risk of clots from The Pill are from studies where each patient was assessed for the outcome (side effect). That's not so with COVID vaccine data now
3/ In some of the COVID vax clinical trials, only 1-out-5 had systematic detailed assessment of side effects. For the other 80%, the trials relied on "spontaneous reporting"
Image
Read 25 tweets
Excited for Priya Bahri’s plenary session on #scicomm at #ICPE20 #RxEpi starting at 11:15am ET today

#pharmacoepidemiology @ISPE_Exchange
Here we go! #icpe2020
"Is silence better than getting it wrong?" when it comes to emerging medication safety issues for patients - Priya Bahri asks of #drugsafety at #ICPE20
Read 9 tweets
It's been 10 years since #OxyContin was re-engineered to make it hard to crush. But #publichealth benefits are still unclear. Here is a brief video of the epidemiology challenges.

vimeo.com/456967594

As guest speaker at FDA Advisory Committee

#RxEpi
#pharmacoepidemiology Image
A *product-centric* worldview, holds that abuse deterrence is primarily the property of the drug, and that that is the PRIMARY thing that changed with the reformulation, especially in the immediate aftermath.
A *person-centric* view holds that abuse deterrence is not merely a property of the drug, but rather an interaction between engineering and society, between physiochemical properties and point-of-prescribing medical decisions.
Read 9 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!